Stocks · Health care · Biological Products, (No Diagnostic Substances)

Replimune Group, Inc.

REPL Clue Score21
United States Fiscal year ends March CIK 0001737953 Results filed 28 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Kapil Dhingra
2 Nov 2026
Director
Sold after exercise
21,500
$19.00
$408.50K
Kapil Dhingra
9 Dec 2025
Director
Sold after exercise
3,169
$10.40
$32.96K

What was left out

Form 4 filings counted 40
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 3
Sales straight out of an exercise 2
Sales at will 13
Transactions with no price 0
Shares from compensation/vesting 974,245
History held since 25 Jul 2018